Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.60

-1.1%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$278.10M
EPS-1.4000
P/E Ratio-1.97
Earnings Date08/12/2026

catx

Net Common Stock Issuance

Last Annual Value

10.36M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

CATX · AMEX
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.36M
205.3%N/AN/A 
21.36M
N/AN/AN/A
-10.00M
N/AN/AN/A
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
656.00K
34.6%-69.2%-25.2%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
215.63M
N/A-8.2%N/A
26.82M
N/A-19.8%N/A
HSDT logo
Solana Company
NASDAQ:HSDT
467.03M
656.9%85.7%N/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.6, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.6